- Home
- RMR vs VNDA Comparison
RMR vs VNDA Comparison
Compare RMR & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMR | VNDA |
|---|---|---|
| Founded | 1986 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.2M | 361.4M |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RMR | VNDA |
|---|---|---|
| Price | $19.55 | $5.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.00 | $14.90 |
| AVG Volume (30 Days) | 103.2K | ★ 907.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $700,284,000.00 | $216,105,000.00 |
| Revenue This Year | $259.61 | $21.35 |
| Revenue Next Year | $2.45 | $37.40 |
| P/E Ratio | $20.63 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $14.27 | $4.27 |
| 52 Week High | $21.45 | $9.91 |
Technical Indicators
Market Signals| Indicator | RMR | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 48.33 |
| Support Level | $18.90 | $4.94 |
| Resistance Level | $20.52 | $5.50 |
| Average True Range (ATR) | 0.40 | 0.20 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 33.45 | 38.24 |
Price Performance
Historical ComparisonAbout RMR The RMR Group Inc.
The RMR Group Inc is a U.S. based real estate investment manager engaged in commercial real estate, private capital, and credit strategies. Its portfolio covers various commercial real estate asset classes, and it manages investments across various industries, geographies and asset classes.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.